25-Desacetylrifapentine
APC-1801
25-Desacetylrifapentine
Cat. No.
APC-1801
CAS No.
79039-56-8
MF
C45H62N4O11
MW
835
25-Desacetylrifapentine is the active metabolite of rifapentine.
Need help? Our team of experienced experts is here for you with full support.
Technical Data
Description
Storage and Shipping
References
Product Name
CAS No.
79039-56-8
MF
C45H62N4O11
MW
835
Specification
98%
Description
25-Desacetylrifapentine is the active metabolite of rifapentine. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g Availability: In stock
Documents
Certificate of Analysis (COA), Specification Sheet, HPLC, 1HNMR, 13CNMR, IR, MS, Safety Data Sheet (SDS/MSDS) etc.
Storage and Shipping
Store in a cool and dry place, avoid strong light and high temperature
References
[1]. Reith K, et al. Disposition and metabolism of 14C-rifapentine in healthy volunteers[J]. Drug Metabolism and Disposition, 1998, 26(8): 732-738. PMID: 9698286.
[2]. Keung AC, et al. Single-dose pharmacokinetics of rifapentine in women[J]. Journal of Pharmacokinetics and Biopharmaceutics, 1998, 26(1): 75-85. PMID: 9773393.
[3]. 25-Desacetyl rifapentine active metabolite product information. Benchchem.
[4]. 25-Desacetylrifapentine. PubChem CID: 135564528. National Institutes of Health (NIH).
[2]. Keung AC, et al. Single-dose pharmacokinetics of rifapentine in women[J]. Journal of Pharmacokinetics and Biopharmaceutics, 1998, 26(1): 75-85. PMID: 9773393.
[3]. 25-Desacetyl rifapentine active metabolite product information. Benchchem.
[4]. 25-Desacetylrifapentine. PubChem CID: 135564528. National Institutes of Health (NIH).
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.